Table 2.

Summary of the characteristics of CAR in clinical studies.

Parameter	Participants’ conditions	cut-off value	Low/ High(N)	Outcome	AUC	Clinical findings	Reference
CAR	Elderly patients with operable NSCLC	0.28	59/49	OS	0.59	CAR is a prognostic marker, but GPS is not.	[17]
	Patients in pN2-stage IIIA with LADC	0.6	122/25	RFS	–	CAR is a prognostic marker, better than GPS, mGPS, Hs-mGPS, and PNI.	[30]
	Patients with operable NSCLC	0.424	492/125	DFS, OS	–	CAR is a prognostic marker.	[31]
	Patients with advanced NSCLC	0.2357	287/149	OS	0.700	CAR is a prognostic marker, better than GPS, mGPS, NLR, PLR and MLR.	[32]
	Chinese patients with NSCLC	0.14/0.22	148/110/129	OS	–	CAR is a prognostic marker, better than CRP, Alb.	[33]
	Patients with advanced NSCLC	0.35	38/39	OS	–	CAR may be a cheap, easy, and effective tool for predicting the death and its time of hospitalized NSCLC patients better than CRP.	[34]
	Patients with NSCLC underwent surgery	0.4	320/172	RFS	–	CAR and GPS may be independent risk factors for early recurrence.	[4]
	Patients with NSCLC underwent surgical resection	0.156	116/480	RFS, OS	0.587	CAR is a prognostic marker, better than GPS, mGPS.	[35]
	Patients with NSCLC treated with nivolumab	0.83	74/39	PFS, OS	–	CAR may be predictive of therapeutic response to nivolumab and long-term survival in NSCLC patients better than GPS, and NLR.	[36]

NSCLC: non-small cell lung cancer; LADC: lung adenocarcinoma; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; RFS: relapse-free survival; DFS: disease-free survival; PFS: progression-free survival; N: number of patients.